BioLineRx : Report of Periodic or Interim Report -March 26, 2024 at 08:26 am EDT

SECURITIES AND EXCHANGE COMMISSION


WASHINGTON, D.C. 20549


FORM 6-K


REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE...

Related Keywords

China ,Washington ,District Of Columbia ,United States ,Israel ,Russia ,Ukraine ,Modiin ,Israel General ,Russian ,American ,Gloria Biosciences ,Moran Meir ,Philipa Serlin ,Philip Serlin ,States John Lacey ,Columbia University ,National Comprehensive Cancer Network ,Twitter ,Exchange Commission ,Linkedin ,Washington University ,Exchange Commission On ,Biolinerx Ltd ,Securities Exchange ,American Society Of Hematology ,Washington University School Of Medicine ,Principal Executive Offices ,Securities Exchange Act ,Linerx Reports ,Recent Corporate ,Healthcare Common Procedure Coding System ,Chief Executive Officer ,Orphan Drug Designation ,Orphan Drug ,Hematopoietic Cell ,American Society ,Annual Meeting ,Drug Evaluation ,National Medical Products Administration ,Ductal Adenocarcinoma ,Cell Disease ,Washington University School ,Year Ended December ,Kreos Capital ,Private Securities Litigation Reform Act ,Sci Advisors ,Markets ,